pleas
cite
articl
ward
ab
wilson
ia
innov
structurebas
antigen
design
immun
monitor
next
gener
vaccin
j
u
r
n
l
p
r
e
p
r
f
highligtht
immunofocus
strategi
structurebas
vaccin
design
structurebas
vaccin
design
rsv
f
influenza
ha
env
structurebas
vaccin
design
translat
clinic
recent
explos
atomiclevel
structur
glycoprotein
compris
surfac
antigen
human
envelop
virus
rsv
influenza
hepat
c
hiv
provid
tremend
opportun
ration
structurebas
vaccin
design
sever
concept
structurebas
vaccin
design
put
practic
well
along
preclin
clinic
implement
test
design
immunogen
provid
key
insight
abil
induc
desir
immun
respons
name
neutral
antibodi
mani
immunogen
human
clinic
trial
repres
first
wave
design
like
requir
continu
tweak
elabor
achiev
ultim
result
ever
increasingli
breadth
potenc
consider
effort
invest
germlin
target
epitop
focus
improv
immun
present
multival
nanoparticl
incorpor
review
highlight
recent
advanc
area
prepar
next
gener
immunogen
subsequ
round
iter
vaccin
develop
j
u
r
n
l
p
r
e
p
r
f
j
u
r
n
l
p
r
e
p
r
f
elicit
neutral
antibodi
strong
correl
success
vaccin
antibodi
typic
target
essenti
compon
viral
lifecycl
surfac
glycoprotein
enabl
cell
entri
bind
host
receptor
facilit
membran
fusion
viral
antigen
includ
influenza
viru
hemagglutinin
human
immunodefici
viru
hiv
envelop
hepat
c
viru
protein
respiratori
syncyti
viru
rsv
f
passiv
administr
antibodi
target
protein
hiv
broadli
neutral
antibodi
bnab
proven
effect
suppress
viremia
hivinfect
individu
studi
provid
proofofconcept
similar
antibodi
could
induc
vaccin
suffici
potenc
breadth
halflif
individu
could
protect
diseas
acquisit
larg
clinic
trial
known
amp
current
ongo
test
concept
hiv
prevent
provid
import
benchmark
term
titer
potenc
requir
block
transmiss
hiv
ampstudyorg
remark
progress
isol
antibodi
natur
infect
immun
use
function
bcell
screen
antigen
specif
bcell
isol
technolog
led
acceler
progress
advanc
mani
field
enabl
structur
definit
key
epitop
viral
surfac
antigen
structur
turn
enabl
revers
vaccinolog
mani
parallel
pursuit
ongo
wide
varieti
viral
microbi
pathogen
purpos
review
focu
rsv
influenza
hiv
flagship
pathogen
structurebas
vaccin
design
nice
highlight
differ
goal
ration
design
process
immunofocus
crossreact
germlin
target
somat
hypermut
review
highlight
desir
outcom
incorpor
design
immunogen
aforement
pathogen
fig
concept
immunofocus
simpli
describ
maxim
ontarget
antibodi
respons
desir
epitop
minim
offtarget
antibodi
respons
mani
wide
employ
vaccin
induct
appropri
antibodi
high
potenc
durabl
readili
accomplish
human
immun
inactiv
virus
viru
like
particl
vlp
howev
rsv
f
vlp
induc
desir
antibodi
respons
least
level
suffici
protect
primari
hurdl
rsv
larg
abund
rsv
f
postfus
conform
surfac
vlp
antibodi
recogn
conform
easili
induc
protect
therebi
act
distract
competitor
efficaci
respons
prefus
conform
rsv
f
potenti
solut
problem
came
stabil
prefus
conform
rsv
f
feat
accomplish
mclellan
colleagu
stabil
form
antigen
preferenti
induc
neutral
antibodi
appropri
prefus
epitop
provid
import
proofofconcept
current
test
clinic
trial
subunit
vaccin
character
antibodi
induc
prefus
rsv
f
along
correspond
structur
reveal
divers
antibodi
respons
critic
epitop
protect
therebi
enabl
opportun
immunogen
design
aim
focus
antibodi
respons
even
similarli
hiv
envelop
glycoprotein
env
stabil
prefus
conform
test
human
clinic
trial
approach
success
induc
protect
neutral
antibodi
respons
macaqu
singl
strain
demonstr
anoth
import
proofofconcept
vaccineinduc
antibodi
protect
repeat
viral
challeng
season
influenza
vaccin
induc
antibodi
quit
narrow
strain
specif
thu
stabil
prefus
conform
env
ha
alon
suffici
induc
broad
immun
key
rsv
f
induc
antibodi
conserv
readili
access
epitop
present
prefus
conform
immunofocus
one
specif
site
surfac
prefus
glycoprotein
requir
gener
crossreact
broad
immun
variabl
virus
influenza
hiv
antibodi
must
hone
specif
conserv
function
epitop
dispers
amidst
surfac
variabl
highli
glycosyl
larg
divers
circul
hiv
strain
season
zoonot
antigen
drift
influenza
present
enorm
hurdl
achiev
neutral
breadth
influenza
hemagglutinin
ha
stem
highli
conserv
region
although
less
access
compar
immunogen
head
region
surfac
antigen
broadli
neutral
antibodi
bnab
discov
provid
hope
appropri
design
immunogen
bnab
elicit
sever
concept
test
achiev
crossreact
includ
headless
miniha
dispens
much
immunogen
head
domain
present
stem
epitop
headswap
chimer
immunogen
vari
ha
head
usual
zoonot
seen
human
reduceelimin
memori
recal
respons
keep
stem
attempt
boost
stalkspecif
respons
also
ongo
effort
broaden
immun
respons
conserv
receptor
bind
site
within
variabl
influenza
ha
head
recent
describ
strategi
wherein
differ
strain
present
singl
mosaic
vlp
effect
promot
crossreact
respons
receptor
bind
domain
fusion
peptid
fp
highli
conserv
recent
emerg
target
epitop
bnab
identifi
capabl
broadli
neutral
divers
virus
eg
fp
much
access
antibodi
compar
viral
glycoprotein
ha
fp
deepli
buri
insid
structur
prefus
state
one
approach
focu
respons
fp
repeat
immun
copi
fp
display
carrier
protein
keyhol
limpet
hemacyanin
klh
follow
booster
immun
env
trimer
spike
present
fp
nativ
context
approach
produc
encourag
respons
anim
neutral
breadth
mice
macaqu
respect
panel
divers
hiv
isol
concept
develop
human
clinic
trial
immunofocus
highli
conserv
epitop
may
suffici
case
elicit
crossreact
bnab
antibodi
necessarili
endow
abil
matur
along
pathway
becom
bnab
capabl
neutral
divers
virus
thu
research
test
concept
activ
particular
germlin
bcell
precursor
known
potenti
concept
advanc
hiv
shown
bnab
often
strict
requir
particular
germlin
usag
v
j
long
short
complementar
determin
region
cdr
particular
heavylight
chain
pair
etc
class
receptor
bind
site
bnab
requir
well
defin
includ
gene
usag
light
chain
short
compar
normal
length
schief
lab
develop
immunogen
eod
present
bind
site
epitop
evolv
bind
antibodi
germlin
precursor
ki
mice
immunogen
shown
stimul
precursor
enrich
antibodi
appropri
properti
also
demonstr
b
cell
precursor
frequenc
bind
affin
eod
immunogen
critic
determin
success
expans
germin
center
well
character
parameter
eod
concept
test
human
result
expect
midtol
antibodi
signatur
well
defin
next
gener
sequenc
ng
critic
tool
determin
vaccin
induc
expand
desir
precursor
healthi
human
volunt
product
character
promis
antibodi
base
ng
data
coupl
threedimension
structur
complex
eod
immunogen
enabl
improv
immunogen
inform
design
boost
immunogen
matur
toward
respons
germlin
target
strategi
extend
addit
epitop
env
includ
supersit
target
mani
antibodi
recent
bnab
problem
becom
even
difficult
due
requir
long
loop
junction
divers
easi
control
elicit
particular
cdr
sequenc
known
bind
composit
glycan
protein
epitop
one
import
requisit
research
profil
human
antibodi
repertoir
identifi
quantit
bona
fide
human
b
cell
precursor
human
popul
emerg
field
deep
sequenc
human
antibodi
repertoir
therefor
serv
multipl
purpos
valid
germlin
target
approach
identif
appropri
precursor
vaccin
design
benchmark
success
immunogen
select
enrich
appropri
b
cell
upon
immun
anim
uniqu
b
cell
repertoir
mice
human
b
cell
express
bnab
germlin
heavi
andor
light
chain
emerg
critic
model
assess
improv
germlinetarget
immunogen
strategi
model
continu
improv
knockin
mice
rapidli
gener
use
even
abil
immunofocu
conserv
epitop
appropri
germlin
bcell
bnab
usual
requir
larg
amount
somat
hypermut
acquir
rang
properti
enabl
broad
crossreact
activ
infect
particularli
constant
antigen
exposur
continu
antigen
drift
natur
driver
high
shm
context
protein
subunit
vaccin
abil
drive
shm
remain
much
larger
hurdl
anoth
issu
key
mutat
develop
breadth
found
tradit
aid
hotspot
coin
improb
mutat
repres
hurdl
bnab
develop
potenti
prime
boost
strategi
howev
shepherd
shm
toward
bnab
proofofconcept
demonstr
number
year
ago
much
recent
effort
place
deliveri
persist
antigen
germin
center
promot
somat
hypermut
continu
deliveri
antigen
multival
antigen
present
adjuv
technolog
includ
immun
checkpoint
modult
promot
germin
center
activ
may
help
overcom
limit
protein
subunit
immunogen
mani
concept
must
test
empir
final
nucleic
acid
deliveri
immunogen
particularli
mrna
emerg
platform
potenti
speed
immunogen
test
potenti
reduc
manufactur
cost
immunogen
design
conduct
atomiclevel
precis
experiment
vaccin
must
test
anim
eventu
human
whose
immun
repertoir
inher
differ
heterogen
even
amongst
individu
speci
larg
divers
bcell
repertoir
result
genet
immun
histori
regular
bcell
turnov
campaign
sequenc
antibodyom
begin
dissect
divers
may
inform
genet
potenti
human
respond
design
immunogen
understand
type
rang
antibodi
respons
epitop
target
design
immunogen
critic
compon
feedback
loop
thu
next
gener
sequenc
ng
baselin
repertoir
antigenspecif
repertoir
post
vaccin
critic
compon
vaccin
design
order
monitor
germlin
usag
extent
somat
hypermut
addit
sequencelevel
understand
antibodi
respons
knowledg
epitop
target
structur
detail
interact
site
critic
tradit
serolog
use
scan
mutagenesi
viral
neutral
monoclon
antibodi
isol
continu
valuabl
new
assay
emerg
acceler
process
one
approach
deep
mutat
scan
combin
deep
mutat
scan
viral
growth
presenc
antibodi
ng
surviv
virus
enabl
map
epitop
function
mutat
requir
recognit
antibodi
singl
particl
electron
microscopi
polyclon
epitop
map
empem
anoth
excit
recent
develop
techniqu
abl
visual
antibodi
respons
directli
serum
em
imag
provid
immedi
feedback
regard
onand
offtarget
antibodi
respons
timedepend
manner
reveal
potenti
differ
respons
individu
anim
mode
immunogen
deliveri
adjuv
etc
data
util
immedi
immunogen
redesign
circumv
need
conduct
timeconsum
viral
mutant
neutral
assay
isol
monoclon
antibodi
field
structurebas
vaccin
design
rapidli
matur
appli
wide
varieti
pathogen
desir
antibodi
discov
structur
solv
complex
antigen
start
point
gener
antigen
seri
antigen
immunofocu
antibodi
respons
site
vulner
excitingli
new
antigen
target
still
uncov
provid
new
opportun
appli
ration
approach
exampl
influenza
viru
recent
studi
rediscov
neuraminidas
na
promis
target
furthermor
newli
identifi
class
epitop
ha
name
interfac
head
subunit
also
found
target
broad
protect
activ
exampl
demonstr
keep
explor
new
site
vulner
may
exploit
immunogen
design
use
approach
describ
review
limit
rsv
influenza
hiv
mani
similar
effort
ongo
creat
protein
subunit
vaccin
pathogen
ebola
lassa
dengu
other
surprisingli
much
effort
current
focus
produc
vaccin
base
prefus
structur
spike
protein
viral
surfac
mani
lesson
learn
pathogen
directli
appli
progress
proceed
unpreced
pace
remark
first
structur
protein
trimer
took
week
produc
sequenc
becam
avail
verg
molecular
control
immun
respons
use
ration
design
immunogen
tool
probe
respons
human
therebi
circumv
need
larg
empir
efficaci
trial
importantli
mani
concept
current
test
human
delin
tabl
technolog
continu
improv
atomiclevel
knowledg
antibodyantigen
recognit
mode
interact
remain
linchpin
immunogen
design
provid
opportun
novel
vaccin
beyond
pathogen
includ
cancer
autoimmun
neurodegener
ref
paper
demonstr
humanderiv
bnab
passiv
infus
hivinfect
individu
taken
antiretrovir
therapi
art
suppress
viremia
develop
extend
period
time
importantli
two
differ
bnab
requir
suppress
escap
mutant
observ
prior
studi
use
monotherapi
addit
vivo
efficaci
studi
also
found
patient
viral
rebound
suppress
beyond
halflif
antibodi
author
propos
unexpect
posit
outcom
may
result
bnab
form
immun
complex
viru
result
favor
present
antigen
germin
center
either
boost
exist
antibodi
induc
new
one
small
scale
human
clinic
trial
stabil
prefus
form
rsv
f
demonstr
fold
increas
neutral
activ
serum
compar
immunogen
antibodi
respons
demonstr
present
rsv
f
stabil
form
preferenti
induc
higher
neutral
respons
studi
demonstr
hiv
env
trimer
stabil
prefus
conform
capabl
elicit
neutral
antibodi
protect
repeat
intrarect
viral
challeng
studi
also
enabl
determin
antibodi
concentr
requir
protect
import
correl
set
target
threshold
induct
neutral
antibodi
hiv
env
trimer
test
human
provid
import
inform
comparison
human
antibodi
respons
macaqu
anim
model
use
immunogen
studi
describ
first
human
clinic
trial
aim
induc
influenza
hemagglutinin
ha
stalkdirect
antibodi
via
immun
chimer
ha
antigen
common
stalk
variabl
head
domain
data
show
form
ha
express
inactiv
influenza
capabl
elicit
crossreact
stalk
direct
antibodi
human
thu
design
approach
preferenti
immunofocus
antibodi
respons
particular
epitop
ha
case
conserv
ha
stem
recent
studi
demonstr
power
immunofocus
via
multival
present
eight
differ
influenza
hemagglutinin
glycoprotein
surfac
ferritin
mice
remark
approach
induc
broadli
cross
reactiv
antibodi
respons
capabl
neutral
wide
rang
influenza
isol
ha
receptor
bind
head
domain
typic
quit
variabl
present
divers
within
singl
mosaic
nanoparticl
abl
elicit
antibodi
capabl
interact
variabl
strainsthu
octaval
ha
antigen
preferenti
engag
b
cell
via
highli
conserv
receptor
bind
site
result
cross
reactiv
respons
ref
paper
demonstr
immunofocus
via
primeboost
strategi
appli
gener
broadli
neutral
antibodi
highli
conserv
fp
hiv
env
isol
bnab
mice
nonhuman
primat
studi
delin
molecular
detail
bnab
recognit
fp
provid
opportun
immunogen
redesign
furthermor
ng
elicit
antibodi
enabl
probe
sequenc
signatur
requir
target
fp
tandem
structur
sequenc
provid
power
platform
assess
immun
respons
drive
immunogen
improv
ref
studi
bnab
ontogeni
evolut
greatli
inform
understand
path
antibodi
undertak
germlin
bnab
bnab
often
requir
mutat
aid
cold
spot
improb
mutat
therefor
repres
larg
hurdl
develop
studi
use
structurebas
design
engin
immunogen
preferenti
induc
mutat
cold
spot
therebi
lower
barrier
evolut
bnab
studi
investig
role
immunogen
bind
affin
b
cell
bnab
precursor
prime
b
cell
variou
frequenc
vivo
importantli
work
provid
proofofconcept
appropri
affin
engin
immunogen
prime
b
cell
frequenc
base
sequenc
human
antibodi
repertoir
realist
model
ref
tour
de
forc
describ
full
panopli
germlinetarget
immunogen
design
test
studi
began
structur
known
bnab
target
supersit
structurebas
comput
design
mammalian
display
conduct
gener
immunogen
bind
germlinerevert
next
immunogen
use
probe
precursor
b
cell
healthi
human
donor
turn
enabl
structur
studi
immunogen
design
improv
bind
isol
bona
fide
bnab
precursor
optim
immunogen
test
stringent
mous
model
first
bona
fide
precursor
knock
mous
next
precursor
b
cell
mous
adopt
transfer
wild
type
mous
frequenc
similar
found
human
upon
vaccin
mice
germlinetarget
immunogen
success
expand
diversifi
precursor
tour
de
forc
investig
gener
billion
sequenc
heavi
light
chain
ten
healthi
volunt
studi
describ
develop
new
bioinformat
tool
valid
curat
enorm
amount
sequenc
data
data
provid
refer
compar
b
cell
repertoir
differ
peopl
databas
determin
b
cell
precursor
frequenc
critic
variabl
germlinetarget
approach
ref
exemplari
studi
employ
deep
sequenc
studi
antibodi
repertoir
three
healthi
volunt
studi
focus
investig
similar
differ
donor
found
rel
high
frequenc
share
clonotyp
data
provid
invalu
refer
compar
b
cell
repertoir
differ
peopl
databas
determin
b
cell
precursor
frequenc
critic
variabl
germlinetarget
approach
studi
investig
role
slow
antigen
deliveri
improv
antigen
specif
b
cell
respons
nonhuman
primat
immunogen
either
deliv
bolu
fraction
escal
dose
via
slow
deliveri
osmot
pump
latter
method
induc
superior
germin
center
respons
assess
serial
sampl
lymph
node
via
fine
needl
aspir
fna
fna
also
repres
emerg
technolog
immunogen
design
mildli
invas
requir
excis
lymph
node
cours
quench
ongo
immun
respons
monitor
time
studi
engin
phosphoserin
tag
onto
cterminu
hiv
envelop
trimer
immunogen
enabl
attach
adjuv
alum
immun
adjuvantantigen
complex
result
higher
antigen
specif
b
cell
respons
germin
center
similar
slow
releas
antigen
describ
refer
convers
nonalum
coupl
antigen
clear
rapidli
lower
b
cell
respons
author
also
show
antigen
traffick
antigen
present
cell
complex
small
plate
alum
coupl
adjuv
antigen
provid
slow
releas
depot
multival
present
like
respons
superior
immun
respons
rel
convent
vaccin
formul
thu
approach
present
practic
approach
slow
depot
deliveri
antigen
safe
wide
use
adjuv
ref
manuscript
demonstr
role
mannos
bind
lectin
mbl
antigen
traffick
follicular
dendrit
cell
germin
center
gc
hiv
env
immunogen
highli
glycosyl
total
env
mass
correspond
glycan
dens
cluster
glycan
provid
high
avid
surfac
mbl
particularli
array
multival
scaffold
turn
bound
complement
effici
deliv
gc
thu
innat
immun
recognit
shown
play
role
antigen
present
work
describ
deploy
two
compon
selfassembl
nanoparticl
make
multival
subunit
vaccin
engin
nanoparticl
use
present
trimer
antigen
prefus
rsv
f
present
multival
format
neutral
antibodi
titer
gener
improv
fold
therebi
demonstr
subunit
vaccin
made
immunogen
deliv
manner
studi
demonstr
use
deep
mutat
scan
determin
permiss
mutat
viral
antigen
escap
monoclon
antibodi
bnab
data
highli
inform
discrimin
similar
antibodi
whose
neutral
activ
differenti
affect
mutat
viral
mutant
surviv
antibodi
pressur
help
predict
escap
pathway
provid
insight
antibodi
improv
manuscript
describ
excit
new
techniqu
visual
bind
antibodi
particular
antigen
present
serum
immun
anim
use
singl
particl
electron
microscopi
power
new
method
complementari
tradit
serolog
approach
use
determin
correl
neutral
onand
offtarget
antibodi
respons
discoveri
new
immunogen
epitop
compar
individu
anim
antibodi
respons
assay
conduct
moder
throughput
enabl
near
real
time
evalu
immun
respons
assess
prime
boost
desir
antibodi
respons
final
method
shown
amen
high
resolut
singl
particl
cryoem
provid
molecular
detail
antibodyantigen
interact
rapidli
inform
immunogen
redesign
j
u
r
n
l
p
r
e
p
r
f
overview
differ
aspect
structurebas
antigen
design
mani
target
pursu
envelop
glycoprotein
mediat
viral
entri
cell
metast
adopt
differ
conform
carri
function
case
rsv
f
mani
mutat
introduc
stabil
prefus
conform
prefer
state
target
potent
neutral
antibodi
b
influenza
ha
prefus
conform
rel
stabl
except
low
ph
membran
fusion
mani
epitop
undesir
result
straindepend
neutral
antibodi
respons
easili
escap
one
strategi
focu
conserv
ha
stalk
region
elimin
variabl
ha
head
altogeth
make
chimer
ha
conserv
stalk
attach
variabl
head
preexist
immun
c
mani
hiv
env
bnab
restrict
gene
usag
place
constraint
vaccin
design
one
approach
overcom
hurdl
known
germlin
target
epitop
present
small
scaffold
mutat
introduc
bind
specif
high
affin
particular
germlin
b
cell
precursor
much
success
structurebas
antigen
design
protein
subunit
antigen
necessarili
immunogen
thu
mani
effort
ongo
understand
immun
system
respond
protein
subunit
vaccin
develop
new
modal
deliveri
formul
multival
nanoparticl
slow
releas
antigen
alum
depot
